Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

32,500

Employees32,500

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

32,500

Employees32,500

BMY Key Statistics

Market cap

130.90B

Market cap130.90B

Price-Earnings ratio

14.03

Price-Earnings ratio14.03

Dividend yield

3.94%

Dividend yield3.94%

Average volume

13.89M

Average volume13.89M

High today

$64.98

High today$64.98

Low today

$63.35

Low today$63.35

Open price

$64.07

Open price$64.07

Volume

3.04M

Volume3.04M

52 Week high

$68.10

52 Week high$68.10

52 Week low

$42.52

52 Week low$42.52

Stock Snapshot

Bristol-Myers Squibb(BMY) stock is priced at $64.08, giving the company a market capitalization of 130.9B. It carries a P/E multiple of 14.03 and pays a dividend yield of 3.94%.

During the trading session on 2026-08-14, Bristol-Myers Squibb(BMY) shares reached a daily high of $64.98 and a low of $63.35. At a current price of $64.08, the stock is +1.2% higher than the low and still -1.4% under the high.

Trading activity shows a volume of 3.04M, compared to an average daily volume of 13.89M.

The stock's 52-week range extends from a low of $42.52 to a high of $68.10.

BMY News

Benzinga 1h

Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb - Benzinga

...

TipRanks 9h

Balanced Risk-Reward Keeps Bristol-Myers Squibb at Hold as Zenbexus CELMoD Opportunity Awaits Key 2026 Data

William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating on August 4. Unlock powerful investing tools with TipR...

TipRanks 1d

Bristol-Myers Squibb Expands Kidney Pipeline With New Golcadomide Renal Study

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter,...

Analyst ratings

61%

of 31 ratings

Buy

35.5%

Hold

61.3%

Sell

3.2%

More BMY News

Nasdaq 3d

November 20th Options Now Available For Bristol Myers Squibb

Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options become available today, for the November 20th expiration. One of the key inputs that goes in...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.